Iran Saves $120M in One Year with Domestic Nano-Cancer Drug and Advanced Nano-Medicine
WANA (Nov 23) – The domestic production of an advanced nano-medicine and innovative Nano-Cancer Drug—considered among the most cutting-edge targeted cancer therapies—has led to major foreign-currency savings, reduced treatment costs, and improved patient care in Iran during 2024.
This Nano-Cancer Drug, developed for patients with HER2-positive breast cancer, is manufactured using highly sophisticated Antibody–Drug Conjugate (ADC) technology. As a next-generation nano-medicine, its performance relies on nanoscale targeting of tumor cells, making it one of the most precise cancer treatment solutions currently available. According to official sources, the drug has received approval from the Food and Drug Administration and has been granted an export license. It is now produced on an industrial scale and fully meets domestic demand without reliance on imports.
The annual market size of this Nano-Cancer Drug is estimated at over 200,000 vials. Local production of this nano-medicine significantly reduces Iran’s dependence on importing one of the world’s most expensive cancer treatments.
Cancer Survival Rate in Iran Reaches 70%
WANA (Nov 20) – At the 24th National Congress of Medical Oncology and Hematology in Iran, Ardeshir Ghavami-Zadeh, Secretary of the Congress, announced that the survival rate of cancer patients in Iran has reached 70% over the past 20 years, attributing this improvement to advances in early screening and timely diagnosis. Ghavami-Zadeh highlighted lifestyle […]
One of the key advantages of Tedrox as a domestically produced nano-medicine is its remarkable price difference compared with the foreign version. The domestic price is 22 million tomans (around USD 200) per vial, while the imported equivalent costs USD 3,036—more than 15 times higher. This price gap not only eases the financial burden on families but also leads to tens of millions of dollars in foreign-currency savings. In 2024 alone, estimates show that the use of this Nano-Cancer Drug saved Iran around $120 million, including reduced treatment-related and logistical costs, highlighting the strategic importance of nano-medicine in national healthcare innovation.
According to available data, this Nano-Cancer Drug not only replaces imports but also has several million dollars in export potential, enabling Iran to expand its presence in the global market for targeted therapies based on nano-medicine technologies. ADC technology—combining a specific antibody with an active drug—is among the world’s most complex pharmaceutical technologies, and Iran’s entry into nano-medicine production marks a significant technological leap.
Citing the Nanotechnology Headquarters, beyond cost savings and reduced treatment expenses, this nano-medicine has a direct impact on improving the quality of life of cancer patients by offering stable access, consistent treatment, reduced psychological and financial pressure on families, and greater hope for recovery.
